Drug Approval | November 13, 2024
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Subscribe To Our Newsletter & Stay Updated
